Windlas Biotech Limited — PPTs, 12-08-2025: Investor Presentation

Here's a summary of the financial update:

**Financial Highlights:**

Windlas Biotech reported its 10th consecutive record quarter: Revenue hit Rs 210 Cr (+20% YoY), PAT rose 31% YoY to Rs 18 Cr (EPS Rs 8.4). EBITDA climbed 27% YoY to Rs 27 Cr, boosting margins to 12.6%. Gross margin expanded to 38.3%. Net debt-free (FY25 liquidity Rs 213 Cr), paid Rs 12.2 Cr dividend (Rs 5.8/share) for FY25.

**Strategic Initiatives & Growth Drivers:**

Key initiatives include Plant 6 capacity expansion and an enhanced injectable facility. Focus is on boosting efficiencies, expanding dosage forms, capitalizing on CDMO outsourcing, and driving growth in Trade Generics, Exports, and complex generics innovation.

**Business Developments:**

All verticals grew: CDMO revenue up 17.8% YoY to Rs 160 Cr. Trade Generics & Institutional surged 25.2% YoY to Rs 44 Cr (market penetration). Exports grew 45.4% YoY to Rs 6 Cr, expanding international presence.

**Market Position & Competitive Advantage:**

As a leading domestic CDMO serving top Indian pharma, Windlas owns IP for most products. Competitive edge: robust R&D driving complex generic growth and strong regulatory compliance (all 5 plants WHO-GMP). Focus on high-margin chronic therapies.

**Investor Implications:**

Consistent growth, strong profitability, strategic capex, and net debt-free status signal positive potential. Diversified model and shareholder return commitment offer a favorable outlook; execution of expansion plans is key.